Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep 15;10(5):665-71.
doi: 10.5009/gnl15451.

The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer

Sunil Amin  1 , Paolo Boffetta  2 , Aimee L Lucas  1
Affiliations
Review

The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer

Sunil Amin et al. Gut Liver. .

Abstract

Survival from pancreatic cancer remains poor. Conventional treatment has resulted in only marginal improvements in survival compared with survival in the previous several decades. Thus, considerable interest has emerged regarding the potential use of common pharmaceutical agents as chemopreventative and chemotherapeutic options. Aspirin, metformin, statins, β-blockers, and bisphosphonates have biologically plausible mechanisms to inhibit pancreatic neoplasia, whereas dipeptidyl-peptidase 4 inhibitors may promote it. Regardless, real-world epidemiological data remain inconclusive. This review examines the hypotheses, evidence, and current state of the literature for each of these medications and their potential roles in the prevention and treatment of pancreatic cancer.

Keywords: Adenocarcinoma; Aspirin; Betablockers; Bisphosphonates; Dipeptidyl-peptidase 4 inhibitors; Epidemiology; Malignancy; Metformin; Pancreas; Statins.

PubMed Disclaimer

References

    1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29. doi: 10.3322/caac.21208. - DOI - PubMed
    1. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review (CSR) 1975–2010. Bethesda: National Cancer Institute; 2013.
    1. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer. 2006;6:130–140. doi: 10.1038/nrc1801. - DOI - PubMed
    1. Yue W, Yang CS, DiPaola RS, Tan XL. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. Cancer Prev Res (Phila) 2014;7:388–397. doi: 10.1158/1940-6207.CAPR-13-0337. - DOI - PubMed
    1. Coogan PF, Rosenberg L, Palmer JR, et al. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev. 2000;9:119–123. - PubMed

MeSH terms

LinkOut - more resources